Regencell Bioscience Holdings Ltd (RGC) Stock
3 members of Congress disclosed 4 trades in RGC since 2017: 1 purchase and 3 sales, most recently Lois Frankel (sale, Jan 8, 2018).
Which members of Congress traded Regencell Bioscience Holdings Ltd (RGC)?
Most recent: Lois Frankel (sale, Jan 8, 2018); records start Mar 28, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lois Frankel D-FL · House | 2018-01-08 | sale | $1k – $15k |
| Michael Bennet D-CO · Senate | 2017-12-08 | sale | $500k – $1.0M |
| Gary Palmer R-AL · House | 2017-04-04 | purchase | $1k – $15k |
| Michael Bennet D-CO · Senate | 2017-03-28 | partial sale | $500k – $1.0M |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all RGC political trades →RGC price chart
Powered by TradingViewWhat does Regencell Bioscience Holdings Ltd do?
Regencell Bioscience Holdings Ltd. is a bioscience company specializing in the research, development, and commercialization of Traditional Chinese Medicine (TCM) formulations. It targets neurocognitive disorders and degenerations, with a primary focus on Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), as well as infectious diseases that impact the immune system. The company develops natural formulas aimed at treating these conditions, emphasizing innovative approaches within the healthcare sector. Through its subsidiary Regencell Limited, incorporated in Hong Kong, it conducts operations from its headquarters in Causeway Bay, Hong Kong. Regencell Bioscience Holdings Ltd. also supports community initiatives via the Regencell Foundation, established in 2017, which provides assistance to children with ADHD and ASD, and elderly individuals with dementia facing financial challenges. This positions the company as an active player in advancing TCM-based therapies for prevalent neurological and immunological health issues, serving patients, families, caregivers, and medical professionals seeking alternative treatments.